Tesamorelin, CJC-1295, and Ipamorelin: What Research Shows About Combining Them

Tesamorelin, CJC-1295, and ipamorelin are three growth hormone–releasing peptides that are often discussed together because they act on different points of the growth hormone (GH) axis. Tesamorelin and CJC-1295 are GHRH analogs that signal the pituitary directly, while ipamorelin is a selective ghrelin-receptor agonist. No large human trial has tested all three as a single blend, so this combination remains a research concept rather than an established therapy.

What Each Peptide Does

Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Tesamorelin is the only peptide in this group with an approved human indication.

CJC-1295 is another GHRH analog sold in two research forms: one bound to a drug affinity complex (DAC) that extends half-life by attaching to albumin, and one without DAC, often called modified GRF 1-29, which clears much faster. Neither form is FDA-approved for human use.

Ipamorelin is a pentapeptide ghrelin mimetic. Animal and early human studies suggest it triggers GH release with less impact on cortisol, prolactin, and appetite than older secretagogues such as GHRP-6. Ipamorelin is not FDA-approved for human use.

Peptide	Class	Primary receptor	FDA status
Tesamorelin	GHRH analog	GHRH receptor	Approved (Egrifta) for HIV-associated lipodystrophy
CJC-1295 (with or without DAC)	GHRH analog	GHRH receptor	Not approved for human use
Ipamorelin	Ghrelin mimetic	GHS-R1a	Not approved for human use

Why People Combine These Peptides

The rationale for pairing a GHRH analog with a ghrelin mimetic is that they hit separate receptors. GHRH analogs act on pituitary GHRH receptors, while ipamorelin acts on GHS-R1a. Some researchers hypothesize that stimulating both pathways creates a larger, more pulsatile GH signal than either peptide alone.

That idea comes mostly from animal data and small, short-term human studies of individual peptides. No controlled trial has shown that a three-peptide blend outperforms a single agent, and sustained IGF-1 elevation remains an unresolved safety question.

Common comparison questions

A frequent search comparison is cjc-1295 ipamorelin vs tesamorelin, which contrasts a GHRH-plus-ghrelin pairing against a single GHRH analog. Another is tesamorelin vs ipamorelin vs cjc 1295, which tends to focus on half-life, receptor selectivity, and regulatory status rather than head-to-head outcomes.

Key Differences at a Glance

Tesamorelin and CJC-1295 share a receptor but differ sharply in how long they stay active. Ipamorelin works through an entirely different pathway, which is why it is usually described as complementary rather than interchangeable.

Feature	Tesamorelin	CJC-1295 with DAC	Ipamorelin
Receptor target	GHRH receptor	GHRH receptor	GHS-R1a (ghrelin)
Approximate half-life	26–38 minutes	Roughly 6–8 days	About 2 hours
GH release pattern	Amplifies natural pulses	Prolonged elevation	Short, sharp pulse
Appetite effect	Minimal	Minimal	Low compared with GHRP-6
FDA status	Approved for one indication	Not approved	Not approved

For older comparisons, cjc 1295 ipamorelin vs sermorelin vs tesamorelin is usually framed around sermorelin's very short half-life and weaker potency relative to the newer analogs.

Research Dosing and Blend Ratios

The ranges below come from published research on individual peptides, not from validated combination protocols. They are listed for informational purposes only and are not a dosing recommendation.

Peptide	Commonly cited research dose	Frequency	Notes
Tesamorelin	1–2 mg	Once daily, subcutaneous	Approved label uses 2 mg daily
CJC-1295 with DAC	1–2 mg	Weekly	Long half-life; sustained IGF-1 rise
CJC-1295 without DAC	100–300 mcg	1–3 times daily	Shorter, more pulse-like action
Ipamorelin	100–300 mcg	1–3 times daily	Frequently paired with a GHRH analog

Blend products marketed under a cjc-1295 ipamorelin tesamorelin stack dosage label vary widely, and the stated amounts often do not match actual vial content. Third-party testing by HPLC and mass spectrometry is the only reliable way to confirm peptide identity and purity.

Whether DAC is present matters a great deal. A formulation described as cjc-1295 no dac ipamorelin tesamorelin behaves very differently from one built on the albumin-bound version, because the half-life difference changes the shape of the GH pulse.

Some researchers also look at metabolic peptides used alongside GH secretagogues, including cjc-1295 ipamorelin mots-c and tesamorelin, although that pairing is studied for mitochondrial and metabolic effects rather than GH release.

Safety, Side Effects, and Legal Status

Tesamorelin is FDA-approved for HIV-associated lipodystrophy but is not approved for general weight loss, bodybuilding, or anti-aging use. CJC-1295 and ipamorelin are not FDA-approved for human use in the United States and are sold as research chemicals.

Documented tesamorelin side effects include injection-site reactions, joint pain, peripheral edema, and elevated IGF-1. Because CJC-1295 and ipamorelin have far less human safety data, their long-term risks are largely unknown.

Chronically elevated GH and IGF-1 can affect glucose metabolism, cause fluid retention, and carry risks that call for medical monitoring. Anyone considering these peptides should discuss it with a healthcare professional rather than self-dosing from a research catalog.

Bottom Line

Tesamorelin, CJC-1295, and ipamorelin target different receptors in the GH axis, and that mechanistic difference is the main reason they are discussed as a stack. Only tesamorelin has an approved human indication, and no clinical trial has validated the three-peptide combination. Sound decisions here depend on clinician oversight and lab monitoring, not on a peptide vendor's dosing chart.

COMMON QUESTIONS

Frequently Asked Questions

Is the tesamorelin, CJC-1295, and ipamorelin stack safe?

No human trial has evaluated all three peptides together, so the combination has no established safety profile. Tesamorelin has documented side effects such as injection-site reactions, joint pain, and elevated IGF-1, while CJC-1295 and ipamorelin have limited human safety data. Anyone considering them should talk with a healthcare professional first.

Is tesamorelin FDA-approved?

Yes. Tesamorelin is FDA-approved as Egrifta for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general weight loss, athletic performance, or anti-aging purposes, and it requires a prescription.

What is a typical dosage for a CJC-1295 and ipamorelin blend?

Published research on individual peptides often cites 100–300 mcg of CJC-1295 without DAC and 100–300 mcg of ipamorelin per injection, one to three times daily. These figures come from separate studies, not from a validated blend protocol, and no standard human dose exists for the combination.